Universe Pharmaceuticals INC Regains Compliance with Nasdaq Minimum Bid Price Requirement
15 November 2022 - 12:00AM
Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a
pharmaceutical producer and distributor in China, today announced
that the Company received a written notification (the “Notification
Letter”) from the Listing Qualifications Department of the Nasdaq
Stock Market LLC (“Nasdaq”) on November 9, 2022, informing the
Company that it has regained compliance with the Nasdaq’s minimum
bid price requirement and the matter is closed.
On July 15, 2022, the Company was notified by
Nasdaq its failure to maintain a minimum bid price of $1.00 per
share for 30 consecutive business days under Nasdaq Listing Rules
5450(a)(1) and 5810(c)(3)(A), and was provided 180 calendar days,
or until January 11, 2023 to regain compliance.
The Notification Letter the Company received
from Nasdaq on November 9, 2022 noted that the Company evidenced a
closing bid price of its ordinary shares at or greater than the
$1.00 per share minimum requirement for the last 10 consecutive
business days, from October 26, 2022 through November 8, 2022.
Nasdaq stated that accordingly, the Company has regained compliance
with Nasdaq Listing Rule 5450(a)(1).
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, headquartered in
Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor
in China. The Company specializes in the manufacturing, marketing,
sales and distribution of traditional Chinese medicine derivatives
products targeting the elderly with the goal of addressing their
physical conditions in the aging process and to promote their
general well-being. The Company also distributes and sells
biomedical drugs, medical instruments, Traditional Chinese Medicine
Pieces, and dietary supplements manufactured by third-party
pharmaceutical companies. Currently, the Company’s products are
sold in 30 provinces of China. For more information, visit the
company’s website at http://www.universe-pharmacy.com/.
Forward-Looking Statements
All statements other than statements of
historical fact in this announcement are forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as “may,” “will,” “expect,” “anticipate,”
“aim,” “estimate,” “intend,” “plan,” “believe,” “potential,”
“continue,” “is/are likely to” or other similar expressions. The
Company undertakes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company’s registration statement and in its other filings with the
U.S. Securities and Exchange Commission.
For more information, please contact:
Ascent Investors Relations LLCTina
XiaoPresidentPhone:
917-609-0333Email: tina.xiao@ascent-ir.com
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Nov 2023 to Nov 2024